-
Targeted-Immunomodulatory Nanomedicines for the Treatment of Autoimmune Diseases via Multiple Administration Routes
27 Dec 2025 01:44 GMT
… medications.3 Some autoimmune diseases are managed with symptomatic treatments … drugs including conventional drugs, antibody drugs, and RNA-related drugs … with multiple sclerosis in a murine multiple sclerosis model … and drug delivery strategies for treatment of …
-
From diagnosis to recovery: South Georgia woman now cancer-free after life-changing treatment
26 Dec 2025 17:56 GMT
… cancer journey after months of treatment, complications, and recovery.
WALB first … doctors believed were due to multiple sclerosis. Further testing revealed the cancer … in a different direction with treatment.
In November, Chaney underwent a …
-
Pharmaceutical Policy in Motion Continued: Trump Inks Nine New Drug Pricing Deals
26 Dec 2025 15:02 GMT
… Deals to Reshape Drug Pricing
The nine … treatment), Amjevita (autoimmune symptom treatment), and Repatha (high cholesterol treatment). These medications … discounted drugs through TrumpRx.gov, including Mayzent, its multiple sclerosis medication.
Sanofi …
-
<![CDATA[NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care ]]>
24 Dec 2025 15:26 GMT
… Strategies to Address Multiple Sclerosis Progression Earlier: Ludwig … and Challenges in Pediatric Multiple Sclerosis Treatment: Lauren B. Krupp … risks of long-term medication use. Furthermore, … currently assessed in multiple sclerosis clinical trials and …
-
Jefferies Maintains Buy Rating on Sanofi Despite Setback in Multiple Sclerosis
24 Dec 2025 12:57 GMT
… application for tolebrutinib in the treatment of multiple sclerosis.
In a research note … 3 trial in primary progressive multiple sclerosis (PPMS), in which tolebrutinib … program, Sanofi's other multiple sclerosis project, remains completely unaffected by …
-
Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B, gets CRL for MS drug
24 Dec 2025 13:44 GMT
-
Sanofi Receives Complete Response Letter from FDA for MS Treatment
24 Dec 2025 07:26 GMT
… , intended for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) in … previously been granted "innovative drug" designation, Sanofi states that …
-
MS Treatment Costs Surge by 125% Over Two Decades
24 Dec 2025 06:52 GMT
TOPLINE:
Annual out-of-pocket costs for multiple sclerosis (MS) care in the US increased by 125% from 2002 to 2021, primarily driven by newer disease-modifying therapies (DMTs), a new study showed.
METHODOLOGY:
Researchers conducted a cross-sectional study …
-
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
24 Dec 2025 06:00 GMT
… multiple sclerosis Paris, December 24, 2025. The US Food and Drug … the treatment of non-relapsing secondary progressive multiple sclerosis and … to developing innovative treatments that address the … and potentially transform the treatment landscape. Standing at …
-
Plant-Derived Exosome-Like Nanoparticles: A Promising Therapeutic for Neurological Disorders and Drug Delivery
25 Dec 2025 18:50 GMT
… BBB, which severely restricts drug delivery to the CNS … potential as promising therapeutic drugs for neurological disorders.
Despite … paucity of truly effective treatments for IS. In … Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. …
About
© 1995-2025